Allakos Announces Phase 2 Lirentelimab Trials in Atopic Derm

– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and...

Related Keywords

Alex Schwartz , Adam Tomasi , Craig Paterson , Denise Powell , Company Nasdaq , Securities Exchange , Allakos Inc , Chief Medical Officer , Eczema Area , Severity Index , Point Improvement , Chronic Spontaneous , Urticaria Activity Score , Weekly Hives Severity Score , Weekly Itch Severity Score , Urticaria Activity Control , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Markets ,